{"prompt": "['ISN/Protocol 7465-CL-0301', 'Sponsor: APGD', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '9. Biochemistry: See [Section 5.5.3 Laboratory Assessments]. Amylase and lipase will only be collected at COE Day 1 of each Cycle. All biochemistry', 'laboratory tests should be collected at the start of the following COE time points: C1D1, C1D8, C1D15 and D1 of each subsequent cycle. If all', 'biochemistry laboratory tests were performed within 7 days prior to the first day of dosing, they do not need to be repeated at C1D1. Biochemistry tests', 'will be sent to a central laboratory for analysis. Local laboratory results may be used to determine eligibility if the C1D1 results from the central', 'laboratory are not available in time for planned C1D1 dosing. In the event that the central laboratory results received after C1D1 dosing are not within', 'eligibility parameters, the subject will still be considered eligible, if local labs met the eligibility criteria, and will not be considered a protocol deviation.', 'Local laboratory results that support eligibility and dosing decisions must be entered into the clinical database. If local laboratory is to be used to support', 'dosing decisions, local laboratory tests will include complete blood count (CBC) with differential, glucose, serum creatinine, ALT and AST. Additional', 'assessments may be done centrally or locally to monitor AEs or as required by dose modification requirements.', '10. If HbA1c was performed within 7 days prior to the first day of COE C1D1 dosing, it does not need to be repeated at COE C1D1. If HbAlc is elevated (>', '6.5%), refer subject to appropriate provider during Cycle 1 for glucose management.', '11. Hematology: See [Section 5.5.3 Laboratory Assessments]. Hematology tests should be collected at the following COE time points: C1D1, C1D8, C1D15', 'and Day 1 of each subsequent cycle. If hematology tests were performed within 7 days prior to the first day of dosing, they do not need to be repeated on', 'C1D1. Hematology tests will be sent to a central laboratory for analysis. Local laboratory results may be used to determine eligibility if the C1D1 results', 'from the central laboratory are not available in time for planned dosing. In the event that the central laboratory results received after C1D1 dosing are not', 'within eligibility parameters, the subject will still be considered eligible if local laboratory results met the eligibility criteria; such events', 'will', 'not', 'be', 'considered protocol deviations. Local laboratory results that support eligibility and dosing decisions must be entered into the clinical database. If local', 'laboratory is to be used to support dosing decisions, local laboratory tests will include CBC with differential, glucose, serum', 'creatinine,', 'ALT', 'and', 'AST.', 'Additional assessments may be done centrally or locally to monitor AEs or as required by dose modification requirements.', '12. ECGs will be read locally. If there is no reason to suspect cardiac issues, ECG will not be required.', '13. Ophthalmologic assessments for subjects with recent ocular complaints (within 3 months of COE consent) are required. Assessments should include the', 'following: visual acuity, slit lamp, tonometry examination and dilated fundus examination. Prior ophthalmologic exam done within', '3', 'months', 'of', 'COE', 'consent is acceptable provided symptoms are not new since the exam. Ophthalmology assessments should be performed per', 'standard', 'of', 'care', 'or', 'if', 'clinically indicated (e.g., subject develops new or worsening ocular symptoms). EOT slit lamp examinations are required for subjects who experience', 'corneal adverse events during the study. EOT slit lamp examinations must be performed > 4 weeks from last dose. Additional eye examinations are to be', 'conducted as clinically indicated.', '14. Imaging will be evaluated within 28 days prior to COE C1D1 dosing and every 56 days ( 7 days) throughout the study. CT scan with contrast', '(chest,', 'abdomen and pelvis) is the preferred modality for tumor assessment. MRI is acceptable if local standard practice or if CT scans are contraindicated in a', 'subject (e.g., subject is allergic to contrast media). All other RECIST approved scanning methods such as x-ray are optional. To ensure comparability,', 'the COE eligibility scan and subsequent assessment of response should be performed using identical techniques as were performed', 'during', 'Arm', 'B', 'participation. The same method should be employed and assessed by the same individual on each occasion if possible. Imaging assessments methods', 'used at Baseline of the main study are to continue to be used throughout the study.', 'Footnotes continued on next page', '14 Sep 2020', 'Astellas', 'Page 124 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '15. QOL will be collected pre-dose on COE C1D1, every 12 weeks during treatment period, EOT visit and at the 30-day follow-up visit. QOL questionnaire', 'completion timing should be calculated based on COE C1D1 dosing. If a visit occurs out of the assessment window, QOL questionnaires should still be', 'completed. QOL questionnaires will be completed by the subject at home on hand-held devices prior to coming to the clinic', 'visit', 'with', 'the', 'exception', 'of', 'COE Day 1 of the first week, the EOT and the follow-up visits at which the QOL questionnaires will be completed by the subject at', 'the', 'clinic.', '16. HRU will be collected pre-dose on COE C1D1. Subsequent questionnaires will be completed monthly (COE Day 1 of every 4 weeks [+7 days]), starting', 'on COE Week 5 Day 1 (timing calculated based on COE C1D1 dosing), and at the EOT and follow-up visit. HRU questionnaires will', 'be', 'completed', 'by', 'the', 'subject at home on hand-held devices prior to coming to the clinic visit with the exception of the COE C1D1, EOT and the follow-up visits at which the', 'HRU questionnaires will be completed by the subject at the clinic.', '17. Subjects that discontinue EV for reasons other than progressive disease will be followed in the long term follow up period per institutional', 'guidelines,', 'but', 'not', 'less frequently than every 3 months to confirm survival status until PFS2 is documented or the subject starts another cancer treatment, whichever is earlier.', 'Phone contact is sufficient for follow up. Additional follow up contacts may be required per sponsor request for analysis purposes.', '18. Contact subjects in the survival follow-up period approximately every 3 months to collect survival status until subject death or study closure.', 'Additional', 'follow-up contacts may be required per sponsor request for analysis purposes.', '19. ATA will be collected at COE Cycles 1, 2, 3, 4, 6, 8 and 10 predose within 24 hrs of the start of the infusion EOT (Date of last dose + 7 days) and follow-up', '(Date of last dose +30 days).', '14 Sep 2020', 'Astellas', 'Page 125 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}